HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (23) Citing Articles via Google Scholar Google Scholar Articles by Newhouse, M. T. Articles by Parry-Billings, M. Search for Related Content PubMed PubMed Citation Articles by Newhouse, M. T. Articles by Parry-Billings, M.

Clickhaler (a Novel Dry Powder Inhaler) Provides Similar Bronchodilation to Pressurized Metered-Dose Inhaler, Even at Low Flow Rates^*

^* From the Barnett Medical Aerosol Research Laboratory (Drs. Newhouse and Nantel and Mss Chambers and Pratt), St. Joseph's Hospital-McMaster University, Hamilton, Ontario, Canada, and ML Laboratories PLC (Dr. Parry-Billings), St. Albans, Hertfordshire, UK.

Study objective: Comparison of the bronchodilator response to an albuterol novel dry powder inhaler (DPI) (Clickhaler [CH]; ML Laboratories PLC; St. Albans, UK) activated at various inspiratory flow rates and to an albuterol pressurized metered-dose inhaler (pMDI) by patients with moderate to moderately severe stable asthma.

Design: Randomized, double-blind, placebo-controlled comparison of the bronchodilator response to albuterol DPI (200 µg) at inspiratory flow rates of approximately 15, 30, and 60 L/min in patients with stable asthma with demonstrated reversibility to albuterol. Active (albuterol via pMDI inhaled at 30 L/min) and placebo controls were included.

Setting: Single center study at the chest/allergy unit of a teaching hospital in Canada.

Patients: Sixteen patients with moderate to moderately severe stable asthma.

Measurements and results: Efficacy end points were FEV₁, FVC, FEV₁/FVC, maximum expiratory flow, and forced expiratory flow between 25% and 75% of vital capacity. Safety end points included heart rate, BP, and tremor. There was no significant difference between the bronchodilator response to albuterol via the CH at 15, 30, and 60 L/min inspiratory flow rate and, at all flow rates, no significant difference was found comparing albuterol CH with the pMDI. All of the techniques for delivering albuterol provided significantly better bronchodilatation than placebo. Adverse events were minimal and did not differ between CH and pMDI or between the various flow rates inhaled through the CH.

Conclusion: A novel passive albuterol DPI (CH) provides a similar bronchodilator response at 15, 30, and 60 L/min inspiratory flow rates compared with a pMDI used optimally.

Key Words: albuterol • bronchodilatation • dry powder inhaler • inspiratory flow rate

This article has been cited by other articles:

				M.T. Newhouse, P. Patel, and M. Parry-Billings Protection against methacholine-induced bronchospasm: salbutamol pMDI versus Clickhaler(R) DPI Eur. Respir. J., May 1, 2003; 21(5): 816 - 820. [Abstract] [Full Text] [PDF]

				F. S F Ram, J. Wright, D. Brocklebank, and J. E S White Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering beta 2 agonists bronchodilators in asthma BMJ, October 20, 2001; 323(7318): 901 - 901. [Abstract] [Full Text]

				P. J. Anderson Delivery Options and Devices for Aerosolized Therapeutics Chest, September 1, 2001; 120(3_suppl): 89S - 93S. [Abstract] [Full Text] [PDF]